Vividion Therapeutics, a preclinical oncology biotech developing small molecule therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Vividion Therapeutics uses its proprietary chemoproteomic platform technology to discover functional pockets on the surface of proteins and to identify small molecules that will selectively bind to those targets. To date, the company has identified covalent small molecules from its library that bind to over 100 unique pockets across over 80 priority targets. Its lead preclinical programs include small molecules that inhibit two key transcription factors, NRF2 and STAT3, and a DNA damage response protein, WRN, which are being advanced for the treatment of cancer and immune diseases. Vividion Therapeutics is developing its STAT3 targeted programs in collaboration with Bristol Myers Squibb and its WRN targeted program in collaboration with Roche. The company plans to submit its first IND in 2022.
The San Diego, CA-based company was founded in 2014 and booked $43 million in collaboration revenue for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol VVID. J.P. Morgan, BofA Securities, and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
